Candel Therapeutics Statistics
Total Valuation
CADL has a market cap or net worth of $614.44 million. The enterprise value is $462.40 million.
| Market Cap | 614.44M |
| Enterprise Value | 462.40M |
Important Dates
The next estimated earnings date is Thursday, November 12, 2026, before market open.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CADL has 76.52 million shares outstanding. The number of shares has increased by 45.29% in one year.
| Current Share Class | 76.52M |
| Shares Outstanding | 76.52M |
| Shares Change (YoY) | +45.29% |
| Shares Change (QoQ) | +18.87% |
| Owned by Insiders (%) | 7.57% |
| Owned by Institutions (%) | 58.93% |
| Float | 60.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 247.76 |
| PB Ratio | 4.85 |
| P/TBV Ratio | 4.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.09, with a Debt / Equity ratio of 0.39.
| Current Ratio | 16.09 |
| Quick Ratio | 15.89 |
| Debt / Equity | 0.39 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.26 |
Financial Efficiency
Return on equity (ROE) is -81.84% and return on invested capital (ROIC) is -32.81%.
| Return on Equity (ROE) | -81.84% |
| Return on Assets (ROA) | -28.64% |
| Return on Invested Capital (ROIC) | -32.81% |
| Return on Capital Employed (ROCE) | -36.83% |
| Weighted Average Cost of Capital (WACC) | 2.91% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.61M |
| Employee Count | 55 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +52.66% in the last 52 weeks. The beta is -0.31, so CADL's price volatility has been lower than the market average.
| Beta (5Y) | -0.31 |
| 52-Week Price Change | +52.66% |
| 50-Day Moving Average | 11.08 |
| 200-Day Moving Average | 8.22 |
| Relative Strength Index (RSI) | 28.45 |
| Average Volume (20 Days) | 990,338 |
Short Selling Information
The latest short interest is 13.00 million, so 16.99% of the outstanding shares have been sold short.
| Short Interest | 13.00M |
| Short Previous Month | 12.34M |
| Short % of Shares Out | 16.99% |
| Short % of Float | 21.59% |
| Short Ratio (days to cover) | 11.02 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -71.98M |
| Pretax Income | -88.53M |
| Net Income | -88.53M |
| EBITDA | -71.30M |
| EBIT | -71.98M |
| Earnings Per Share (EPS) | -$1.44 |
Balance Sheet
The company has $201.57 million in cash and $49.52 million in debt, with a net cash position of $152.05 million or $1.99 per share.
| Cash & Cash Equivalents | 201.57M |
| Total Debt | 49.52M |
| Net Cash | 152.05M |
| Net Cash Per Share | $1.99 |
| Equity (Book Value) | 126.13M |
| Book Value Per Share | 1.66 |
| Working Capital | 191.47M |
Cash Flow
In the last 12 months, operating cash flow was -$56.02 million and capital expenditures -$1.30 million, giving a free cash flow of -$57.32 million.
| Operating Cash Flow | -56.02M |
| Capital Expenditures | -1.30M |
| Depreciation & Amortization | 678,000 |
| Net Borrowing | 41.21M |
| Free Cash Flow | -57.32M |
| FCF Per Share | -$0.75 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CADL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -45.29% |
| Shareholder Yield | -45.29% |
| Earnings Yield | -17.92% |
| FCF Yield | -9.33% |
Analyst Forecast
The average price target for CADL is $22.11, which is 175.34% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $22.11 |
| Price Target Difference | 175.34% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |